C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
CFT1946 數據顯示 BRAF V600X 黑色素瘤、結直腸癌、非小細胞肺癌和腦轉移的臨床前模型中具有前景的單藥和組合活性
WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.
馬薩諸塞州沃特敦，2024年3月5日（GLOBE NEWSWIRE）——致力於推進靶向蛋白質降解科學的臨床階段生物製藥公司C4 Therapeutics, Inc.（C4T）（納斯達克股票代碼：CCC）今天宣佈接受2024年4月5日至10日在加利福尼亞州聖地亞哥舉行的美國癌症研究協會（AACR）2024年年會上的兩份臨床前海報演講。
Details of the posters are as follows:
海報詳情如下：
Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
Abstract Number: 1658
Session Date and Time: Monday April 8, 2024 9:00 AM - 12:30 PM PT
Location: Poster Section 14
Session Title: Cell Signaling Components as Therapeutic Targets
Presenter: Bridget Kreger, Ph.D., principal scientist, biology
標題：CFT1946 是一種強效、選擇性的 BRAF V600X 突變體特異性降解劑，在 BRAF V600X 黑色素瘤、結直腸癌、非小細胞肺癌和腦轉移的臨床前模型中，作爲臨床批准的 BRAF 抑制劑和標準護理組合的單一藥物，表現出優於臨床批准的 BRAF 抑制劑和標準護理組合
摘要編號：1658
會議日期和時間：太平洋時間 2024 年 4 月 8 日星期一上午 9:00-下午 12:30
地點：海報區 14
會議標題：細胞信號成分作爲治療靶標
主持人：Bridget Kreger，博士，生物學首席科學家
Title: CFT8634, a BRD9 BiDAC degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
Abstract Number: 6064
Session Date and Time: Tuesday April 9, 2024 1:30 PM - 5:00 PM PT
Location: Poster Section 30
Session Title: Targeted Protein Degraders
Presenter: Laura Poling, Ph.D., director, biology
標題：CFT8634 是一種 BRD9 bidAC 降解劑，在一部分多骨髓瘤細胞系模型中具有活性，與泊馬度胺或地塞米松聯合使用時具有協同作用
摘要編號：6064
會議日期和時間：太平洋時間 2024 年 4 月 9 日星期二下午 1:30-下午 5:00
地點：海報區 30
會議標題：靶向蛋白質降解劑
主持人：勞拉·波林博士，生物學主任
In November 2023, C4T made the strategic decision to discontinue clinical development of CFT8634 based on clinical data from the Phase 1 trial.
2023 年 11 月，C4T 根據一期試驗的臨床數據，做出了停止 CFT8634 臨床開發的戰略決策。
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
關於 C4 療法
C4 Therapeutics（C4T）（納斯達克股票代碼：CCCC）是一家臨床階段的生物製藥公司，致力於兌現靶向蛋白質降解科學的承諾，創造改變患者生活的新一代藥物。C4T正在通過臨床研究和利用其TORPEDO推進靶向腫瘤學項目 該平台可高效設計和優化小分子藥物，以解決難以治療的疾病。C4T的降解劑藥物旨在利用人體的天然蛋白質回收系統快速降解致病蛋白，從而有可能克服耐藥性、不可藥物靶標和改善患者預後。欲了解更多信息，請訪問 www.c4therapeutics。
About CFT1946
CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E-driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600 mutant solid tumors including non-small cell lung cancer, colorectal cancer and melanoma. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).
關於 CFT1946
CFT1946 是一種口服生物可利用的 bidAC 降解劑，旨在有效和選擇性地針對 BRAF V600X 突變體靶標。在臨床前研究中，CFT1946 在 BRAF v600E 驅動的疾病模型和對 BRAF 抑制劑具有耐藥性的模型中在體內和體外均具有活性。CFT1946 目前正處於 BRAF V600 突變實體瘤的 1 期劑量遞增研究，包括非小細胞肺癌、結直腸癌和黑色素瘤。有關該試驗的更多信息，請訪問www.clinicaltrials.gov（標識符：NCT05668585）。
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
聯繫人：
投資者：
考特尼·索爾伯格
投資者關係高級經理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒體：
Loraine Spreen
企業傳播與患者宣傳高級董事
LSpreen@c4therapeutics.com
譯文內容由第三人軟體翻譯。